# How Treprostinil Medicine Can Treat Interstitial Lung Disease > This patent describes methods to treat a serious lung condition called interstitial lung disease (ILD) by giving patients the medicine treprostinil to reduce lung function decline and improve breathing capacity. - **Patent:** US 12734143 - **Original title:** Treatment for interstitial lung disease - **Granted:** 2026 - **Status:** Active - **Times cited:** 0 - **Field:** biotech, pharmaceutical, healthcare ## What it does This patent provides methods for treating interstitial lung disease (ILD), a condition that causes scarring in the lungs. The core of the method involves administering treprostinil to a patient. The goal is to reduce the worsening of lung function over time and to increase the patient's forced vital capacity (FVC), which is the maximum amount of air they can exhale after a deep breath. For example, a patient with ILD could receive treprostinil to help slow down the progression of their disease and improve their ability to breathe deeply. ## What it does NOT cover - Does not cover treatments for interstitial lung disease that use different medications than treprostinil. - Does not cover the use of treprostinil to treat lung conditions other than interstitial lung disease. - Does not cover methods of improving lung function that do not involve administering treprostinil to a patient. - Does not cover preventing interstitial lung disease before it develops, only treating existing conditions. ## The clever bit The novelty lies in identifying treprostinil, a known drug, as a treatment specifically for interstitial lung disease to reduce pulmonary function decline and increase forced vital capacity, rather than its existing uses for other lung-related conditions. ## Real-world examples 1. Existing treprostinil formulations (e.g., Remodulin, Tyvaso) adapted for ILD treatment. 2. Clinical trials exploring treprostinil's efficacy in patients with interstitial lung disease. ## Why it matters Interstitial lung disease (ILD) is a severe and progressive condition that significantly impairs a patient's breathing and quality of life. Current treatments often only slow its progression. This patent matters because it proposes a new therapeutic application for treprostinil, a drug already known for treating other pulmonary conditions, offering a potential new avenue for managing ILD and improving patient outcomes. ## Frequently asked questions ### What does How Treprostinil Medicine Can Treat Interstitial Lung Disease cover? This patent describes methods to treat a serious lung condition called interstitial lung disease (ILD) by giving patients the medicine treprostinil to reduce lung function decline and improve breathing capacity. ### When does this patent expire? This patent is expected to expire on September 15, 2046, when the invention enters the public domain. ### What problem does this patent solve? Interstitial lung disease (ILD) is a severe and progressive condition that significantly impairs a patient's breathing and quality of life. Current treatments often only slow its progression. This patent matters because it proposes a new therapeutic application for treprostinil, a drug already known for treating other pulmonary conditions, offering a potential new avenue for managing ILD and improving patient outcomes. ### What does this patent NOT cover? Does not cover treatments for interstitial lung disease that use different medications than treprostinil. **Full plain-English explainer:** https://patentbrief.org/patent/us/12734143/treatment-for-interstitial-lung-disease **Original patent:** https://patents.google.com/patent/US12734143 --- _Source: PatentBrief — https://patentbrief.org. Patent facts are from public records; the plain-English explanation is PatentBrief's._ ## Related patents Semantically similar inventions in the PatentBrief corpus: - [How to Treat Severe Lung Infections Using Ceftolozane and Tazobactam](https://patentbrief.org/patent/us/10028963/biktarvy-bictegravir-taf-ftc) — A medical treatment method for severe, hospital-acquired pneumonia using a specific, recurring intravenous dose of the antibiotic combination ceftolozane and tazobactam. - [Making Ivacaftor Easier for the Body to Absorb](https://patentbrief.org/patent/us/8410274/kalydeco-ivacaftor) — A patent describing a specific way to turn a drug molecule into an amorphous solid to help the body absorb it more effectively. - [Using Purified Fish Oil Derivatives to Lower Triglycerides Alongside Statins](https://patentbrief.org/patent/us/8710041/imbruvica-ibrutinib-formulation) — A medical treatment method using a specific high-dose, purified EPA supplement to lower triglycerides in patients already taking statin medication. - [Blocking RUNX1 to Stop Eye Scarring and Cell Changes](https://patentbrief.org/patent/us/12735707/runx1-inhibition-for-treatment-of-proliferative-vitreoretinopathy-and) — This patent describes using methods and substances to stop certain cells in the eye from growing too much or changing their type, which can cause serious eye conditions like scarring. - [Using Antibodies to Protect Transplanted Organs from Damage](https://patentbrief.org/patent/us/10400035/ocrevus-ocrelizumab) — A medical method for preserving transplanted organs by using specific antibodies to block a protein that causes inflammation and blood vessel leakage.